Invention Grant
- Patent Title: Antibodies against CD73 and uses thereof
-
Application No.: US16117183Application Date: 2018-08-30
-
Publication No.: US11352440B2Publication Date: 2022-06-07
- Inventor: Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Jeanne M. DiGiorgio
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/40 ; C07K16/28 ; C07K16/30 ; G01N33/573 ; A61K47/68 ; A61K45/06 ; G01N33/574 ; A61K39/00

Abstract:
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Public/Granted literature
- US20190062456A1 ANTIBODIES AGAINST CD73 AND USES THEREOF Public/Granted day:2019-02-28
Information query